Skip to content

Ketamine's Effect Changes the Cortical Electrophysiological Activity Related to Semantic Affective Dimension of Pain

Ketamine's Effect Changes the Cortical Electrophysiological Activity Related to Semantic Affective Dimension of Pain: a Placebo-controlled Study in Healthy Male Subjects

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03915938
Enrollment
24
Registered
2019-04-16
Start date
2017-01-02
Completion date
2017-11-30
Last updated
2019-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Pain, Chronic Pain, Widespread, Schizophrenia

Keywords

Ketamine, ERP, Oddball

Brief summary

This is a clinical trial that intend to determine the effects of S-ketamine on event-related potentials associated with semantic affective pain-processing

Detailed description

Ketamine is a unique anesthetic with neural effects that are distinct from more commonly-used γ-aminobutyric acid agonists. Evidence suggest that analgesic effect of ketamine is primarily related to the affective than the sensorial aspects of pain interpretation. The investigators investigated whether ketamine, a noncompetitive NMDA antagonist, would modify the perceived emotional valence of pain-related words when compared to non-pain-related ones in healthy volunteers. Using a single session double-blind parallel placebo-controlled design, 24 healthy volunteers were randomized to receive intravenous S-ketamine (n=12) or placebo (n=12). During infusion (plasmatic target of 60 ng/ml), the effects of ketamine were recorded using EEG and oddball behavioral data was monitored. Evoked potentials (N200 and P300 components) were recorded during performance of a semantic written word oddball task containing pain-related (targets) and non-pain-related words (standards). Expected results: The findings of this study can help in the understanding of neurophysiologic mechanisms involved in ketamine's effects both in psychiatric diseases as in the treatment of postoperative acute and chronic pain.

Interventions

DRUGKetamine

S-ketamine will be administered in precalculated infusion rates to obtain a plasmatic level of 60 ng/ml

DRUGPlacebo

Administered in an identical way than ketamine.

Sponsors

Hospital de Clinicas de Porto Alegre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* male healthy subjects with higher education level

Exclusion criteria

* do not understand Portuguese language * obese patients (BMI \> 27 kg/m2) * use of NSAID, steroids, analgesics, anticonvulsant drugs, as well as alpha and beta-blockers * score ≥ 13 on Beck II Questionnaire * sleep deprivation in the night before evaluation

Design outcomes

Primary

MeasureTime frameDescription
AUC of the grand averaged mean differences between ERPs elicited by target and non-target wordsup to 60 minEEG will be recorded during all task time. The main outcome will be the area under de curve (AUC) of the grand averaged mean differences between event-related potencials (ERPs) elicited by target and non-target words at 100-200, 300-500 and 800-900 ms after stimulus presentation for parietal electrophysiological signal (Pz). The ERPs represent the averaged voltage of several trials.

Secondary

MeasureTime frameDescription
Word ratings related to the semantic valenceup to 60 minAfter viewing each word, volunteers were asked to classify them according to the semantic valence in the following categories: positive, negative or neutral.
Response times (behavioural oddball data)up to 60 minResponse times to word classification in oddball task

Other

MeasureTime frameDescription
Subjective euphoria ratingup to 60 minEuphoria will be rated using an analogue visual scale ranging of 0 to 10.
Subjective sedation ratingup to 60 minSedation will be rated using an analogue visual scale ranging of 0 (completely awake) to 100 (sleeping).

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026